Evidence map›Paper›PMID 34709570›Full record

ArticleMolecular biology reports2022

Isopimpinellin extends antiangiogenic effect through overexpression of miR-15b-5p and downregulating angiogenic stimulators.

Sambhavi Bhagavatheeswaran, Vinu Ramachandran, Sambantham Shanmugam, Anandan Balakrishnan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Quantitative Analysis of Isopimpinellin fromMolecules (Basel, Switzerland) · 2024
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sambhavi BhagavatheeswaranDepartment of Genetics, Dr. ALM PG IBMS, University of Madras, Chennai, Tamilnadu, 600113, India.
Vinu RamachandranDepartment of Genetics, Dr. ALM PG IBMS, University of Madras, Chennai, Tamilnadu, 600113, India.
Sambantham ShanmugamDepartment of Pharmacology and Neuro Science, Texas Tech University Health Sciences, Lubbock, TX, 79430, USA.
Anandan BalakrishnanDepartment of Genetics, Dr. ALM PG IBMS, University of Madras, Chennai, Tamilnadu, 600113, India. anand_gem@yahoo.com.ORCID http://orcid.org/0000-0003-4747-3799
University of Madras · INTexas Tech University · US

Funding

science and engineering research board ECR/2015/000265
6 · The paper itself

Abstract

backgroundAngiogenesis is the formation of new blood vessels from an existing vasculature through a series of processes such as activation, proliferation, and directed migration of endothelial cells. Angiogenesis is instrumental in the metastatic spread of tumors. Isopimpinellin, a furanocoumarin group of phytochemicals, is an anticarcinogenic agent. However, no studies have proven its antiangiogenic effects. The current study thus aimed to screen the antiangiogenic effect of isopimpinellin. METHODS AND

resultsHuman Umblical Vein Endothelial Cell (HUVEC) as an in vitro model and zebrafish embryos as an in vivo model was used in this study. The experimental results showed that isopimpinellin effectively inhibited HUVEC proliferation, invasion, migration, and tube formation, which are the key steps in angiogenesis by markedly suppressing the expression of pro-angiogenic genes VEGF, AKT, and HIF-1α. In addition, isopimpinellin exerts its anti-angiogenic effect through the regulation of miR-15b-5p and miR-542-3p. Furthermore, in zebrafish embryos, isopimpinellin inhibited the development of intersegmental vessels (ISVs) through the significant downregulation of all pro-angiogenic genes vegf, vegfr2, survivin, angpt-1, angpt-2, and tie-2.

conclusionCollectively, these experimental findings offer novel insights into the antiangiogenic nature of isopimpinellin and open new avenues for therapeutic approaches.

Indexed as

Up-RegulationAngiogenesis InhibitorsAnimalsCell MovementCell ProliferationFurocoumarinsGene Expression Regulation, DevelopmentalHumansHuman Umbilical Vein Endothelial CellsHypoxia-Inducible Factor 1, alpha SubunitMicroRNAsModels, AnimalProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor AZebrafishAngiogenesis InhibitorsFurocoumarinsHypoxia-Inducible Factor 1, alpha SubunitisopimpinellinMicroRNAsMIRN15 microRNA, humanProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor AAngiogenesisHUVECIsopimpinellinmiRNAZebrafish

Identifiers

PMID34709570
OpenAlexW3209754339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.